Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
3(75.0%)
Phase 3
1(25.0%)
4Total
Phase 1(3)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT01028794Phase 1Completed

Autologous Bone Marrow Mononuclear Cell Transplantation for Stroke Patients

Role: collaborator

NCT00221182Phase 1Terminated

Stem Cell Study for Patients With Heart Disease

Role: collaborator

NCT00221156Phase 3Completed

Acarbose and Secondary Prevention After Coronary Stenting

Role: collaborator

NCT00221143Phase 1Completed

Stem Cell Study for Patients With Leg Ulcer/Gangrene

Role: collaborator

All 4 trials loaded